SCHEMBL4284442

SCHEMBL4284442

O=C(NCc1ccccc1)c1cc(-c2cccs2)on1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 1.00
NPC1 O15118 7/20 1.00
NPSR1 Q6W5P4 2/20 1.00
MEN1 O00255 5/20 0.80
KMT2A Q03164 5/20 0.80
ALDH1A1 P00352 5/20 0.80
PLEC Q15149 1/20 0.80
SMN1; SMN2 Q16637 9/20 0.77
TP53 P04637 3/20 0.77
LMNA P02545 4/20 0.75
ESR1 P03372 1/20 0.75
HPGD P15428 3/20 0.69
KDM4E B2RXH2 3/20 0.69
CYP1A2 P05177 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C19 P33261 1/20 0.60
HTT P42858 1/20 0.59
MAPT P10636 1/20 0.59
THRB P10828 1/20 0.59
HSD17B10 Q99714 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9911605 0.91 RAB9A (0.84) RAB9ANPC1NPSR1MEN1KMT2A
SCHEMBL4290049 0.89 MEN1 (1.00) RAB9ANPC1NPSR1MEN1KMT2A
SCHEMBL4284349 0.88 RAB9A (0.78) RAB9ANPC1NPSR1MEN1KMT2A
SCHEMBL4283494 0.87 RAB9A (1.00) RAB9ANPC1NPSR1MEN1KMT2A
SCHEMBL4284405 0.85 RAB9A (0.73) RAB9ANPC1NPSR1MEN1KMT2A
SCHEMBL1474497 0.84 RAB9A (0.72) RAB9ANPC1NPSR1MEN1KMT2A
SCHEMBL4293055 0.83 RAB9A (0.71) RAB9ANPC1NPSR1MEN1KMT2A
SCHEMBL9911645 0.83 RAB9A (0.77) RAB9ANPC1NPSR1MEN1KMT2A
SCHEMBL4282973 0.83 RAB9A (0.74) RAB9ANPC1NPSR1MEN1KMT2A
SCHEMBL20507264 0.82 RAB9A (0.72) RAB9ANPC1NPSR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same SIERRA SCIENCES, LLC (US) 2025-09-02 US disclosed
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same SIERRA SCIENCES, LLC 2025-06-05 US disclosed
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME SIERRA SCIENCES INC. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same TERT, RNGTT, TERF2 RAB9A 4044/4885NPC1 2894/4885NPSR1 4839/4885
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same TERT, TELO2, POT1 RAB9A 4662/4885NPC1 4442/4885NPSR1 4860/4885
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME TERT, TERF2, RNMT RAB9A 3970/4885NPC1 2996/4885NPSR1 4818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.